HAEMOPHILIA

The national blueprint for future factor VIII inhibitor clinical trials: NHLBI State of the Science (SOS) Workshop on factor VIII inhibitors

The bleeding score: Useful in predicting spontaneous bleeding events in adults with bleeding of unknown cause?

Measurement of joint health in persons with haemophilia: A systematic review of the measurement properties of haemophilia‐specific instruments

An overview of turoctocog alfa pegol (N8‐GP; ESPEROCT®) assay performance: Implications for postadministration monitoring

Fibrinogen concentrates in hereditary fibrinogen disorders: Past, present and future

Recommendations for the clinical interpretation of genetic variants and presentation of results to patients with inherited bleeding disorders. A UK Haemophilia Centre Doctors’ Organisation Good Practice Paper

Can we compare haemophilia carriers with clotting factor deficiency to male patients with mild haemophilia?

Population‐based surveillance of haemophilia and patient outcomes in Indiana using multiple data sources

From the voices of people with haemophilia A and their caregivers: Challenges with current treatment, their impact on quality of life and desired improvements in future therapies

Comparison of the efficacy and safety of 12‐month low‐dose factor VIII tertiary prophylaxis vs on‐demand treatment in severe haemophilia A children

PEGylated biologics in haemophilia treatment: Current understanding of their long‐term safety

The national blueprint for 21st century data and specimen collection and observational cohort studies: NHLBI State of the Science Workshop on factor VIII inhibitors

Congenital Factor X deficiency in women: A systematic review of the literature

Healthcare professionals in the ‘tainted blood’ era in Canada: Their forgotten emotions

Executive summary of the NHLBI State of the Science (SOS) Workshop: Overview and next steps in generating a national blueprint for future research on factor VIII inhibitors

Consensus statements on vaccination in patients with haemophilia—Results from the Italian haemophilia and vaccinations (HEVA) project

Thrombin and plasmin generation in patients with plasminogen or plasminogen activator inhibitor type 1 deficiency

Prevalence and risk factors associated with hepatitis C among Brazilian male patients with haemophilia: A long‐term follow‐up

Cross‐sectional comparative study of pharmacokinetics and efficacy between sucrose‐formulated recombinant factor VIII (Kogenate®) and BAY 81‐8973 (Kovaltry®) in patients with severe or moderate haemophilia A in prophylaxis

Factor VIII prophylaxis effects outweigh other hemostasis contributors in predicting severe haemophilia A joint outcomes

Emicizumab prophylaxis to facilitate anticoagulant therapy for management of intra‐atrial thrombosis in severe haemophilia with an inhibitor

The effects of six‐week resistance, aerobic and combined exercises on the pro‐inflammatory and anti‐inflammatory markers in overweight patients with moderate haemophilia A: A randomized controlled trial

Evaluation of pre‐analytic heat treatment protocol used in the CDC Nijmegen‐Bethesda assay for heat inactivation of extended half‐life haemophilia treatment products

An update on the new classification of Ehlers‐Danlos syndrome and review of the causes of bleeding in this population

Whole blood ristocetin‐induced platelet impedance aggregometry does not reflect clinical severity in patients with type 1 von Willebrand disease

Effect of low‐dose factor VIII prophylaxis therapy on bone mineral density and 25(OH) vitamin D level in children with severe haemophilia A

Reagent substitution in the chromogenic Bethesda assay for factor VIII inhibitors

Expecting the unexpected: Acquired haemophilia A in a patient with homozygous factor V deficiency

Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B

The prevalence and burden of hand and wrist bleeds in von Willebrand disease

Screening urinalysis demonstrates that haematuria is a frequent finding in persons with haemophilia treated at a paediatric haemophilia treatment centre

Characteristics and management of the haemophilia‐associated pseudotumours

Haemophilia Experiences, Results and Opportunities (HERO study) in Brazil: Assessment of the psychosocial effects of haemophilia in patients and caregivers

Age‐related severity and distribution of haemophilic arthropathy of the knee, ankle and elbow among Chinese patients with haemophilia

Rhenium‐188 radiosynovectomy for chronic haemophilic synovitis: Evaluation of its safety and efficacy in haemophilic patients

Coagulation factor VIII is vital for increasing global coagulation after physical exercise

The Paediatric Haemophilia Activities List (pedHAL) in routine assessment: changes over time, child‐parent agreement and informative domains

Acute Hepatitis E Virus infection in a hemophilic patient with acquired inhibitor during immune tolerance therapy according to modified Bonn‐Malmö protocol

Nutritional status of children and adolescents with haemophilia in Basra, Iraq

Predictive factors of immune tolerance treatment response in severe haemophilia A patients with inhibitors: A real‐world report from a single centre, mixed retrospective‐prospective long‐term study

Why plasma‐derived factor VIII?

Clinical application of Web Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS‐Hemo): Patterns of blood sampling and patient characteristics among clinician users

Continuous infusion of simoctocog alfa in haemophilia A patients undergoing surgeries

Coping strategies in young and adult haemophilia patients: A tool for the adaptation to the disease

A rare presentation of homozygous factor X deficiency in a pregnant patient: A case report and review of the literature

Factor IX inhibitors: Clinical and laboratory profiles of two patients with severe haemophilia B

Periprocedural management of von Willebrand disease: An institutional experience